The TACL group investigators for TACL protocol T2005-003 “Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)”: Paul Gaynon, MD, Children’s Hospital Los Angeles, CA; Elizabeth Raetz, MD, New York University Medical Center, New York, NY; Nobuko Hijiya, MD, Children's Memorial Medical Center at Chicago, IL; Raymond Hutchinson, MD, C.S. Mott Children’s Hospital, Ann Arbor, MI; Yoav Messinger, MD, Children’s Hospital & Clinics of Minnesota, Minneapolis, MN; Julie Glade-Bender, MD, Children’s Hospital New York-Presbyterian, New York, NY; Lewis Silverman, MD, Dana-Farber Cancer Institute and Children's Hospital, Boston, MA; Amanda Termuelsen, MD, Miller Children’s Hospital, Long Beach, CA; Laura Martin, MD, Nationwide Children’s Hospital, Columbus, OH; Todd Cooper, DO, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA; Steve DuBois, MD, UCSF School of Medicine, San Francisco, CA; Patrick Brown, MD, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; Clare Twist, MD, Stanford University Medical Center, Palo Alto, CA; Hans Hitzler, MD, Hospital for Sick Children, Toronto, Canada; Javier Oesterheld, MD, Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC; Blythe Thomson, MD, Seattle Children’s Hospital, Seattle, WA; David Ziegler, MD, Sydney Children’s Hospital, Australia; Luciano Dalla-Pozza, MD, The Children’s Hospital at Westmead, Australia; Caroline Hastings, MD, Children’s Hospital Oakland; John Goldberg, MD, University of Miami Cancer Center, Miami, FL; Michael Burke, MD, University of Minnesota Children’s Hospital, Minneapolis, MN.